Literature DB >> 8972677

Association of Chlamydia pneumoniae IgA antibodies with recently symptomatic asthma.

D L Hahn1, T Anttila, P Saikku.   

Abstract

To determine whether recently diagnosed adult-onset asthma is associated with serologic evidence of chronic Chlamydia pneumoniae infection, we performed a case-control study in a primary care clinic of cases with asthma (25 adults reporting first symptoms of asthma within 2 years of enrollment) and 45 concurrently enrolled sex and age (+/- 10 years) matched non-asthmatic controls with normal pulmonary function. C. pneumoniae-specific IgA, IgG and IgG4 antibodies, and circulating immune complexes (CIC) were measured by microimmunofluorescence testing. Results showed that frequencies of IgG titres > or = 16 (92%), IgG4 titres > or = 16 (20%) and CIC > or = 4 (60%) in asthma patients were not significantly different from those of controls. However, asthmatics had a significantly higher prevalence of C. pneumoniae-specific IgA titres > or = 10 (72% of cases vs 44% of controls, P < 0.05). After adjustment for the effects of age, sex and smoking, the odds ratio for an association of IgA and asthma was 3.7 (95% confidence interval 1.2-11.5). We conclude that recently symptomatic reversible airway obstruction in adults is associated with the presence of C. pneumoniae-specific IgA antibodies, a proposed indicator of chronic respiratory C. pneumoniae infection.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8972677      PMCID: PMC2271656          DOI: 10.1017/s0950268800059197

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  14 in total

1.  Association of Chlamydia pneumoniae (strain TWAR) infection with wheezing, asthmatic bronchitis, and adult-onset asthma.

Authors:  D L Hahn; R W Dodge; R Golubjatnikov
Journal:  JAMA       Date:  1991-07-10       Impact factor: 56.272

2.  Formalinized Chlamydia trachomatis organisms as antigen in the micro-immunofluorescence test.

Authors:  S P Wang; C C Kuo; J T Grayston
Journal:  J Clin Microbiol       Date:  1979-08       Impact factor: 5.948

3.  Prevalence rates of asthma in developing countries and their comparison with those in Europe and North America.

Authors:  J B Cookson
Journal:  Chest       Date:  1987-06       Impact factor: 9.410

Review 4.  Structure and function of immunoglobulin A.

Authors:  T B Tomasi; H M Grey
Journal:  Prog Allergy       Date:  1972

5.  Interference of immunoglobulin G (IgG) antibodies in IgA antibody determinations of Chlamydia pneumoniae by microimmunofluorescence test.

Authors:  T Jauhiainen; T Tuomi; M Leinonen; J D Kark; P Saikku
Journal:  J Clin Microbiol       Date:  1994-03       Impact factor: 5.948

6.  Epidemiology of asthma.

Authors:  P Burney
Journal:  Allergy       Date:  1993       Impact factor: 13.146

7.  Smoking is a potential confounder of the Chlamydia pneumoniae-coronary artery disease association.

Authors:  D L Hahn; R Golubjatnikov
Journal:  Arterioscler Thromb       Date:  1992-08

8.  Chlamydia pneumoniae (TWAR): a common agent in acute bronchitis.

Authors:  G Falck; L Heyman; J Gnarpe; H Gnarpe
Journal:  Scand J Infect Dis       Date:  1994

9.  Chlamydia pneumoniae-specific circulating immune complexes in patients with chronic coronary heart disease.

Authors:  E Linnanmäki; M Leinonen; K Mattila; M S Nieminen; V Valtonen; P Saikku
Journal:  Circulation       Date:  1993-04       Impact factor: 29.690

10.  Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study.

Authors:  P Saikku; M Leinonen; L Tenkanen; E Linnanmäki; M R Ekman; V Manninen; M Mänttäri; M H Frick; J K Huttunen
Journal:  Ann Intern Med       Date:  1992-02-15       Impact factor: 25.391

View more
  15 in total

1.  Comparison of throat swabs with sputum specimens for the detection of Chlamydia pneumoniae antigen by direct immunofluorescence.

Authors:  P Garnett; O Brogan; C Lafong; C Fox
Journal:  J Clin Pathol       Date:  1998-04       Impact factor: 3.411

2.  Chlamydophila pneumoniae and Mycoplasma pneumoniae in respiratory specimens of children with chronic lung diseases.

Authors:  N Teig; A Anders; C Schmidt; C Rieger; S Gatermann
Journal:  Thorax       Date:  2005-09-02       Impact factor: 9.139

Review 3.  Pharmacotherapy of severe asthma.

Authors:  Rafael Firszt; Monica Kraft
Journal:  Curr Opin Pharmacol       Date:  2010-05-10       Impact factor: 5.547

4.  Prevalence and persistence of Chlamydia pneumoniae antibodies in healthy laboratory personnel in Finland.

Authors:  Mika Paldanius; Aini Bloigu; Marianne Alho; Maija Leinonen; Pekka Saikku
Journal:  Clin Diagn Lab Immunol       Date:  2005-05

5.  Chlamydia pneumoniae infection associated with uncontrolled asthma: a hospital based cross sectional study.

Authors:  Shally Awasthi; Krishna Kumar Yadav; Jyotsna Agarwal
Journal:  Indian J Pediatr       Date:  2012-06-08       Impact factor: 1.967

6.  Chlamydia pneumoniae Infection and Inflammatory Diseases.

Authors:  Rebecca A Porritt; Timothy R Crother
Journal:  For Immunopathol Dis Therap       Date:  2016

7.  Chlamydia pneumoniae seropositivity in adults with acute ischemic stroke: A case-control study.

Authors:  N K Rai; R Choudhary; R Bhatia; M B Singh; M Tripathi; K Prasad; M V Padma
Journal:  Ann Indian Acad Neurol       Date:  2011-04       Impact factor: 1.383

8.  Respiratory infections precede adult-onset asthma.

Authors:  Aino Rantala; Jouni J K Jaakkola; Maritta S Jaakkola
Journal:  PLoS One       Date:  2011-12-21       Impact factor: 3.240

9.  Secondary outcomes of a pilot randomized trial of azithromycin treatment for asthma.

Authors:  David L Hahn; Mary Beth Plane; Olaimatu S Mahdi; Gerald I Byrne
Journal:  PLoS Clin Trials       Date:  2006-06-30

10.  Association of plasma circulatory markers, Chlamydia pneumoniae, and high sensitive C-reactive protein in coronary artery disease patients of India.

Authors:  Hem Chandra Jha; Pragya Srivastava; Rakesh Sarkar; Jagdish Prasad; Aruna Singh Mittal
Journal:  Mediators Inflamm       Date:  2009-04-05       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.